Renovacare, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
May 14, 2020 at 10:23 pm
Share
RenovaCare, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 3.690 million compared to USD 2.008 million a year ago. Net loss was USD 3.358 million compared to USD 2.120 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.03 a year ago.
RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâs own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâs CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâs own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâs novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.
RENOVACARE, INC. 
